Connor Clark & Lunn Investment Management Ltd. Decreases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Connor Clark & Lunn Investment Management Ltd. cut its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 40.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 22,273 shares of the biopharmaceutical company’s stock after selling 15,008 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Agios Pharmaceuticals were worth $990,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Caxton Associates LP boosted its stake in shares of Agios Pharmaceuticals by 0.7% in the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after purchasing an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in Agios Pharmaceuticals by 1.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after acquiring an additional 540 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the second quarter valued at $37,000. Finally, Quest Partners LLC acquired a new stake in Agios Pharmaceuticals in the second quarter valued at $40,000.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 11.20 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Stock Down 0.7 %

Shares of AGIO opened at $58.66 on Thursday. The firm has a 50-day moving average price of $47.93 and a 200 day moving average price of $45.04. The firm has a market capitalization of $3.35 billion, a PE ratio of 5.12 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 52-week low of $20.96 and a 52-week high of $62.58.

Wall Street Analyst Weigh In

AGIO has been the topic of several recent analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Scotiabank upped their price target on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Finally, Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $52.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.